Monobromobimane Sulfide Trapping for Early ADRD Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a lack of reliable and affordable early tests for Alzheimer's disease and related dementias (ADRD), which can begin years before outward symptoms manifest, posing a significant economic and societal burden as the population ages.
Innovation Solution
A method involving the determination of biochemical sulfide levels in a plasma sample using alkaline buffer with monobromobiamine to diagnose ADRD, with threshold levels of total sulfide at 1.32 μM or 1.64 μM, and optionally considering free sulfide levels, and administration of sulfide reducers like sulfide scavengers, inhibitors, or NO promoters to treat ADRD.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional diagnostic methods are used for Alzheimer's disease, then the diagnosis can be made, but the diagnostic accuracy is insufficient and the test is not reliable for early detection
Solution Approach 1:
The invention measures biochemical sulfide levels (a specific chemical parameter) in plasma samples to diagnose ADRD. By changing from traditional clinical assessment parameters to quantitative biochemical parameters, the diagnostic accuracy and reliability are improved, enabling early detection before outward symptoms manifest.
2Reliability
If early intervention is implemented for ADRD, then economic and societal benefits are achieved, but there is a lack of reliable early tests to enable such intervention
Solution Approach 1:
The invention enables preliminary diagnosis of ADRD by measuring biochemical sulfide levels before outward symptoms appear. This preliminary action allows early intervention to be implemented, preventing the loss of time and enabling economic and societal benefits to be achieved through timely treatment.
3Measurement precision
If biochemical sulfide levels are measured to diagnose ADRD, then diagnostic accuracy is improved, but the test complexity increases
Solution Approach 1:
The invention replaces complex mechanical and clinical assessment systems with a biochemical measurement system that quantifies sulfide levels. This substitution simplifies the diagnostic process while improving accuracy, as the biochemical test provides objective numerical data rather than requiring complex clinical evaluation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Provides a reliable early diagnostic for ADRD and potential therapeutic intervention by modulating sulfide levels, offering improved diagnostic accuracy and treatment options for mild to severe ADRD.
Implementation Method 1
determining a level of a biochemical sulfide in the plasma sample from the patient by trapping volatilized H2S in the plasma sample using alkaline buffer with monobromobiamine
Data Source
AI summary
A method of diagnosing Alzheimer's disease and related dementias (ADRD) in a patient comprising obtaining a plasma sample from the patient; determining a level of a biochemical sulfide in the plasma sample from the subject by trapping volatilized H2S in the plasma sample using alkaline buffer with monobromobiamine, and detecting the level of biochemical sulfide in the plasma sample, the biochemical sulfide being one of acid-labile sulfide, bound sulfide, and total sulfide; and diagnosing the patient with ADRD when the level of the biochemical sulfide is at least an elevated threshold level for the biochemical sulfide.